![]() |
|
|
METABOLISM, TRANSPORT, AND PHARMACOGENOMICS
School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (M.J.Z.-G., K.N., X.T., A.S.B., K.L.R.B.); and Medical Science Division, Fox Chase Cancer Center, Philadelphia, Pennsylvania (K.L., M.G.B., G.D.K.)
Although glucuronide and sulfate conjugates of many drugs and endogenous compounds undergo appreciable hepatic basolateral excretion into sinusoidal blood, the mechanisms that govern basolateral translocation of these hydrophilic metabolites have not been completely elucidated. In the present study, the involvement in this process of Mrp3 and Mrp4, two basolateral efflux transporters, was evaluated by analyzing the hepatic basolateral excretion of the glucuronide and sulfate metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3/ and Abcc4/ mice using a cassette dosing approach. In the livers of Abcc3/ and Abcc4/ mice, the basolateral excretory clearance of acetaminophen sulfate was reduced
20 and
20%, 4-methylumbelliferyl sulfate was reduced
50 and
65%, and harmol sulfate was decreased
30 and
45%, respectively. The basolateral excretory clearance of acetaminophen glucuronide, 4-methylumbelliferyl glucuronide, and harmol glucuronide was reduced by
96,
85, and
40%, respectively, in the livers of Abcc3/ mice. In contrast, basolateral excretory clearance of these glucuronide conjugates was unaffected by the absence of Mrp4. These results provide the first direct evidence that Mrp3 and Mrp4 participate in the hepatic basolateral excretion of sulfate conjugates, although additional mechanism(s) are likely involved. In addition, they reveal that Mrp3 mediates the hepatic basolateral excretion of diverse glucuronide conjugates.
Address correspondence to: Dr. Kim L.R. Brouwer, University of North Carolina School of Pharmacy, Kerr Hall, CB 7360, Chapel Hill, NC 27599-7360. E-mail: kbrouwer{at}unc.edu
This article has been cited by other articles:
![]() |
Y. Kitamura, M. Hirouchi, H. Kusuhara, J. D. Schuetz, and Y. Sugiyama Increasing Systemic Exposure of Methotrexate by Active Efflux Mediated by Multidrug Resistance-Associated Protein 3 (Mrp3/Abcc3) J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 465 - 473. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sakamoto, H. Kusuhara, K. Horie, K. Takahashi, T. Baba, J. Ishizaki, and Y. Sugiyama Identification of the Transporters Involved in the Hepatobiliary Transport and Intestinal Efflux of Methyl 1-(3,4-Dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) Glucuronide, a Pharmacologically Active Metabolite of S-8921 Drug Metab. Dispos., August 1, 2008; 36(8): 1553 - 1561. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Aleksunes, S. N. Campion, M. J. Goedken, and J. E. Manautou Acquired Resistance to Acetaminophen Hepatotoxicity is Associated with Induction of Multidrug Resistance-Associated Protein 4 (Mrp4) in Proliferating Hepatocytes Toxicol. Sci., August 1, 2008; 104(2): 261 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kato, S. Takahara, S. Kato, Y. Kubo, Y. Sai, I. Tamai, H. Yabuuchi, and A. Tsuji Involvement of Multidrug Resistance-Associated Protein 2 (Abcc2) in Molecular Weight-Dependent Biliary Excretion of {beta}-Lactam Antibiotics Drug Metab. Dispos., June 1, 2008; 36(6): 1088 - 1096. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Abla, L. W. Chinn, T. Nakamura, L. Liu, C. C. Huang, S. J. Johns, M. Kawamoto, D. Stryke, T. R. Taylor, T. E. Ferrin, et al. The Human Multidrug Resistance Protein 4 (MRP4, ABCC4): Functional Analysis of a Highly Polymorphic Gene J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 859 - 868. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Tian, B. Swift, M. J. Zamek-Gliszczynski, M. G. Belinsky, G. D. Kruh, and K. L. R. Brouwer Impact of Basolateral Multidrug Resistance-Associated Protein (Mrp) 3 and Mrp4 on the Hepatobiliary Disposition of Fexofenadine in Perfused Mouse Livers Drug Metab. Dispos., May 1, 2008; 36(5): 911 - 915. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mizuno, T. Takahashi, H. Kusuhara, J. D. Schuetz, T. Niwa, and Y. Sugiyama Evaluation of the Role of Breast Cancer Resistance Protein (BCRP/ABCG2) and Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in The Urinary Excretion of Sulfate and Glucuronide Metabolites of Edaravone (MCI-186; 3-Methyl-1-phenyl-2-pyrazolin-5-one) Drug Metab. Dispos., November 1, 2007; 35(11): 2045 - 2052. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Lickteig, C. D. Fisher, L. M. Augustine, L. M. Aleksunes, D. G. Besselsen, A. L. Slitt, J. E. Manautou, and N. J. Cherrington Efflux Transporter Expression and Acetaminophen Metabolite Excretion Are Altered in Rodent Models of Nonalcoholic Fatty Liver Disease Drug Metab. Dispos., October 1, 2007; 35(10): 1970 - 1978. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. van de Wetering, N. Zelcer, A. Kuil, W. Feddema, M. Hillebrand, M. L. H. Vlaming, A. H. Schinkel, J. H. Beijnen, and P. Borst Multidrug Resistance Proteins 2 and 3 Provide Alternative Routes for Hepatic Excretion of Morphine-Glucuronides Mol. Pharmacol., August 1, 2007; 72(2): 387 - 394. [Abstract] [Full Text] [PDF] |
||||